This article is more than 5 years old. Information may no longer be current.

FGFR inhibitor improves survival in previously treated cholangiocarcinoma

Incyte announced positive overall response rate and progression-free survival results for pemigatinib, a selective fibroblast growth factor receptor inhibitor under evaluation for patients who failed previous treatment for advanced or metastatic cholangiocarcinoma, according to a press release.

Treated patients who presented with FGFR2 fusions or rearrangements demonstrated an overall response rate of 36%, the primary endpoint, and median progression free survival of 6.9 months, the secondary endpoint.

“We are excited to share updated data for pemigatinib, which may provide a promising and targeted treatment approach for patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements,” Peter Langmuir, MD, group vice president of targeted therapeutics at Incyte, said in the release. “Patients with advanced cholangiocarcinoma face a poor prognosis, and currently there is no standard of care beyond first-line chemotherapy.”

The phase 2b study comprised 107 patients with FGFR2 fusions or rearrangements, 20 patients with other FGF/FGFR genetic alterations, and 18 patients with no FGF/FGFR genetic alterations.

Additional data from the 107-patient cohort revealed a disease control rate of 82% and that median response duration was 7.4 months. Preliminary overall survival at the latest follow-up was 21.1 months and the investigators will continue to assess the enrolled patients.

Pemigatinib was generally well-tolerated. Serous retinal detachment occurred in 4% of patients with none of the cases resulting in clinical sequelae.

Reference: www.incyte.com